Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could not agree more.
I don’t think they are long for this corporate world as an independent entity.
Murocman
Hard to tell.
The company had almost $12m in cash at the end of the last quarter, and had just under $4m in expenses last quarter.
The company also has an active ATM, that they stated would likely be active through end of this quarter.
Given all that, probably not a new offering but any pop will get diluted via their ATM.
Murocman
Well, if the estimate in the preview was all based on product sales, Bioline missed the mark!
If not, then they exceeded expectations!
Regardless, looks like kind of a slow uptake and start for Aphexda (sp?)
Murocman
Nice with the 9 year old PR!
Had me going there for a hot second 😄
Yes. Have a personal interest as I have heart disease.
Have traded it sporadically.
Disappointed that don’t ever seem to get much traction with this therapy even with good data.
Murocman
I am, but watching from the sidelines in case PD are a repeat of AD (as far as market reaction).
Murocman
Could test $7.50 area if it doesn’t bounce back above $8.50 in the next few days.
Bought some more today and will keep doing so below $10.
Murocman
U.S. Markets are down due to persistent high inflation data, and they may be helping drag the price.
Personally, I think it’s going to be a tough overall environment for US markets to advance much given inflation and interest rates.
That said, there will certainly be stocks that do well if they have solid prospects and good financials.
Unfortunately for Bioline, the jury is still out on both counts!
Murocman
I fear this will go the way of Gamida.
That being said, Bioline has additional assets in development and is not in the dire financial shape Gamida was. Although, they are definitely headed in that direction ……
Murocman
Disappointing to say the least. An approved drug with demand should be generating revenue, not requiring millions in dilution to get it off the ground.
Murocman
This is a text book case of what horrible, incompetent management can do to an otherwise good product/idea.
What an awful turn of events 🤬
Lots of talk and great PR’s but very little in the way of actual revenue and results.
Like you say, until they an actually put up some solid results and earn some trust in being able to execute it will be more of the same.
Murocman
Yeah, uncertainty and doubt about the Parkinson’s data readout is spooking more and more people each day that there isn’t a readout or a schedule for a read out.
It gives the impression the company is stalling trying to make “lemonade out of lemons”
This is self inflicted by the company to some degree as if they would have just said Q1 2024 for data, they would not have created some of this disappointment and doubt.
Also, the very late change to the endpoint on the PD trial is disconcerting as well.
Am hopeful for good data but just watching at this point. Too much risk for me for a bad readout. Been burned before.
Murocman
The company was also featured in a tipranks article saying it’s a compelling investment due to growing revenue and earnings potential given their recent approval.
That probably is hurting either.
Murocman
The question is, can AREC?
So far lots of talk but no production and no revenue.
Murocman
Agreed. Either implies desperation or they’re trying to telegraph that a deal is close.
If it’s the former, maybe an attempted pump to tap an ATM?
If the latter, just finish the deal and announce it!
Murocman
True! If nothing else, it’s nice to see some sustained upward momentum with decent volume.
Murocman
Yep, here we go again……
Indeed ☹️
The flaw in that statement is that Niocorp can actually produce the product.
To date they have shown nothing concrete that they will be able to do so, and nothing that inspires any confidence that they will actually be able to get this mine up and running.
All is “hopium” at this point.
Totally understand. I think we’re all a little crispy from being burned by this company on multiple occasions!
Murocman
I’m not so sure. There is no good reason for the volume today and there aren’t any known catalysts pending.
Volume is over 2x normal and could easily approach 3x before the market closes.
Something going on but it remains to be seen if it’s something imminent we’ll find out about in the next few days.
There is the old wall street adage that volume precedes price, so I guess we’ll see?
Murocman
Something’s afoot on an otherwise nondescript Friday trading day!?
Name 1 new mine or refining facility in the U.S. in the last 5 years that has come online to “secure” the U.S. Supply of critical rare earth minerals?
I can think of exactly zero. For all the hype and bloviating that has been spewed by the U.S. government, they seem to be doing far more to obstruct development rather than actually support it.
The U.S. hasn’t done that to this point so makes you think they would start now!?
Post from another board relevant to ALT:
GLP-1 drugs will_be supply-constrained for_a_few_years, according to the NVO and LLY webcasts at JPM. All in-house and CMO capacity suitable for manufacturing injected GLP-1 drugs is already in service. Moreover, the eventual uptake of oral GLP-1 drugs will not ease the manufacturing bottleneck as much as people might think because the low bioavailability of the oral agents requires large amounts of API.
Signs of life on strong volume and no news during a holiday week…hmmm!
Surprised how much this has tanked in light of stellar data?
Murocman
Showing some life this morning with upwards price action and strong volume….
Outstanding data and financing in place to boot!
Should move up!
Murocman
Approved!
I listened to the Piper Sandler interview today.
Sounds like no real prospects for a partnership, etc. until the launch ramp improves?
Bottom line nothing imminent and I surmise the KOL event is to drum up some interest and increased uptake of Omisurge to help improve the sales ramp.
That’s my take anyway.
Murocman
They have a few facts wrong in that article, namely that BLRX has no products on the market!
The lack of basic fact checking, research and due diligence in “Journalism” these days is the reason everything needs to be taken with a grain of salt an nothing should be trusted at face value.
Murocman
I would think we’d be close to the bottom here? Almost at a 52 week low!
GLTA,
Murocman
OT: You okay Midas? Prayers to you all of Israel.
Murocman
With the level of open hostility by the FDA that was reported during some of the reports from the Livestream on another board, I think you would be wasting your time holding out any hope for the FDA.
I think their best hope is to try and get approval somewhere else, like Israel, or try to sell to someone that can competently develop this therapy.
The biggest loser in all of this are those with ALS.
Murocman
It’s key whether or not the ADCOM and more importantly the FDA, find all of this public input compelling.
You would think so but there’s a lot of bad history here and the FDA is not an organization that easily admits it was wrong.
If they do reject this, I think there will be people with pitchforks and torches after them.
I’d like to say I’m optimistic, but I’ve been burned here before. Will see what the briefings docs say? May dabble into a small position into the ADCOM.
Murocman
You’d think we had gotten a PDUFA delay or something based on this price action!
Sheesh!
The Biden Administration released their revised rules on critical minerals development.
The key takeaway is that they don’t want to encourage development. There’s a 7 cent “dirt tax” for every ton of hard rock that is displaced.
You’d think they want to make dependent on the Chinese. Oh yeah, that’s right….they do.
With leaders like ours, who needs adversaries.
APPROVED!
Murocman